CUV has been relatively slow in their product launch to market. Even Scenesse for EPP (outside USA) appears a tad slow. Pricing is an issue clearly. OTC products 2 and 3 are targeting ‘natural tanning’ and skin cancer. MT2 is unregulated and not only not registered for use through the TGA but actively warned against due to lack of regulated trials and side effects. Not sure about the angst - you can quite easily secure MT2 if you want it. To access Clinuvel’s products you have to wait a bit and pay a lot more (such is the cost of regulated development).
CUV has been relatively slow in their product launch to market....
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.59 |
Change
-0.150(1.02%) |
Mkt cap ! $730.6M | |||
| Open | High | Low | Value | Volume |
| $14.74 | $14.77 | $14.50 | $504.1K | 34.46K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 132 | $14.59 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.64 | 96 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |